TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026 : average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension
Propionyl-l-carnitine improves exercise performance and functional status in patients with claudication
However, as both SCD and vitamin B12 deficiency share the same therapeutic approach, a clinical diagnosis of suspected SCD secondary to vitamin B12 deficiency was made
Wound appearance and healing timeline serve as key indicators
Journal of Clinical Psychopharmacology, 21 (3), 335-339
It is widely chosen for its balance of effectiveness, safety, and long-term skin health support